Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). 

The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Step 0: Pre-Registration

• Patients who need a new biopsy must also give a blood sample for genetic testing.
• Must register to get a study ID number for sample submission.
• The same ID number will be used if moving forward to Step 1.

Step 1: Main Study

• Adults (18 years of age or older) with advanced or returning non-small cell lung cancer (NSCLC) confirmed by a biopsy.
• Must have enough tumor tissue available for testing and agree to send tissue and blood samples for research.
• Can join the study either after cancer progression on a prior treatment or while still on current treatment.
• Must be able to perform normal daily activities and provide informed consent to participate.
• Must agree to allow remaining tissue samples to be used for future research studies.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.